Financial Performance - The company's operating revenue for the first half of 2023 was ¥255,681,233.67, representing a 23.21% increase compared to ¥207,521,874.75 in the same period last year[22]. - The net profit attributable to shareholders was ¥37,975,334.64, up 20.50% from ¥31,515,861.09 year-on-year[22]. - The net profit after deducting non-recurring gains and losses increased by 41.63%, reaching ¥34,373,001.25 compared to ¥24,268,965.07 in the previous year[22]. - The basic and diluted earnings per share rose to ¥0.13, an 18.18% increase from ¥0.11 in the same period last year[22]. - The total assets at the end of the reporting period were ¥1,074,717,678.35, a 3.57% increase from ¥1,037,692,058.04 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 2.36% to ¥873,916,302.08 from ¥853,758,112.73 at the end of the previous year[22]. - The gross profit margin for the pharmaceutical hollow capsule manufacturing industry improved to 29.95%, an increase of 2.20% from the previous year[47]. - The company reported a profit margin of approximately 14.9% for the first half of 2023, compared to 15.2% in the same period of 2022[126]. - The total comprehensive income for the first half of 2023 was ¥38,362,806.65, compared to ¥31,614,620.84 in the first half of 2022, reflecting a growth of 21.5%[126]. Cash Flow and Investments - The net cash flow from operating activities significantly decreased by 86.98%, amounting to ¥3,033,130.35 compared to ¥23,293,267.85 in the same period last year[22]. - Cash and cash equivalents increased by 116.98% to ¥28,418,125.31, primarily due to improved cash flow from investment activities[43]. - The net cash flow from investment activities was CNY 43,409,804.17, a turnaround from a negative CNY 170,909,163.63 in the first half of 2022[131]. - Cash inflow from investment activities totaled CNY 49,817,403.51, down 83.2% from CNY 296,870,230.61 year-on-year[131]. - Cash outflow from investment activities decreased to CNY 6,407,599.34, compared to CNY 467,779,394.24 in the previous year, a reduction of 98.6%[131]. - The net cash flow from financing activities was negative at CNY -18,211,412.10, slightly improved from CNY -19,923,044.79 in the same period last year[132]. Market and Operational Strategy - The company plans to enhance its raw material security system to adapt to market changes and maintain stable growth[30]. - The company has established a comprehensive procurement, production, and sales system to optimize operational efficiency[34]. - The company focuses on R&D, having developed advanced technologies for enteric-coated capsules and obtained several patents[39]. - The company has built a large marketing network, serving over 30 provinces and establishing partnerships with major pharmaceutical companies[38]. - The company emphasizes a customer-centric approach, offering customized marketing services to enhance client relationships[38]. - The company is actively responding to industry challenges, including drug procurement policies and rising raw material costs, to strengthen its market position[35]. - The company plans to optimize product structure and enhance market expansion efforts in response to external challenges[63]. - The company plans to expand its market presence and invest in new product development to drive future growth[138]. Risk Management - The company has outlined potential risks and corresponding measures in its management discussion section, which investors are encouraged to review[4]. - The company faced risks related to policy regulation, raw material price fluctuations, product price reductions, and human resources[63][64]. - The company plans to continue monitoring and adjusting its credit loss provisions based on economic forecasts and historical data[182]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 25,705[103]. - The largest shareholder, Shandong Lutai Holding Group, holds 29.99% of the shares, totaling 89,699,541 shares[104]. - The second-largest shareholder, Yu Chunming, holds 8.06% with 24,103,274 shares[104]. - The company has not undergone any significant changes in shareholding structure during the reporting period[101]. - The company has not reported any changes in the actual controller during the reporting period[107]. Compliance and Governance - The report indicates that there are no significant changes in the company's accounting policies or financial reporting standards during the reporting period[23]. - The financial statements for the first half of 2023 were approved by the board of directors on August 18, 2023[149]. - The company has no significant doubts regarding its ability to continue as a going concern for the next 12 months[150]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position, operating results, and cash flows accurately[152]. Environmental and Social Responsibility - The company has implemented a unified management system for environmental protection and established responsibility targets for its environmental work[75]. - The company actively participates in social welfare activities, including voluntary blood donation and support for disadvantaged employees[76].

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-023 安徽黄山胶囊股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 安徽黄山胶囊股份有限公司（以下简称"公司"）第五届监事会第三次会议 通知于2023年8月8日以电子邮件及电话等方式向公司全体监事发出，会议于2023 年8月18日上午11:00在公司一楼会议室召开。本次会议应到监事3人，实到监事3 人。列席本次会议的有董事会秘书张文政先生。会议由监事张新华先生主持，本 次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司 章程》的规定。 二、监事会会议审议情况 1.审议通过《2023 年半年度报告及摘要》。 具体内容详见公司于 2023 年 8 月 19 日在指定信息披露媒体《证券时报》、 《上海证券报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn） 披露的《2023 年半年度报告摘要》（公告编号：2023-021）和《2023 年半年度 报告》。 表决结果：同意 3 票，反 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-025 安徽黄山胶囊股份有限公司 关于以专利权质押担保向银行申请贷款的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽黄山胶囊股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日召开 第五届董事会第三次会议和第五届监事会第三次会议，审议通过了《关于以专利 权质押担保向银行申请贷款的议案》，同意公司以 10 项专利作为质押担保向中 国农业银行股份有限公司旌德县支行（以下简称"农业银行"）申请贷款人民币 2,500 万元。现将相关情况公告如下： 一、交易概述 为进一步拓宽公司融资渠道，优化资产负债结构，公司第五届董事会第三次 会议和第五届监事会第三次会议，审议通过了《关于以专利权质押担保向银行申 请贷款的议案》，同意公司以 10 项专利作为质押担保向农业银行申请贷款人民 币 2,500 万元，在额度范围内授权公司管理层根据公司实际用款需求办理有关贷 款及质押手续，并代表公司签署办理贷款手续所需合同、协议及其他法律文件。 根据《深圳证券交易所股票上市规则》和《公司章程》等相关规 ...

非经营性资金占用及其他关联资金往来情况汇总表 2023年半年度 编制单位：安徽黄山胶囊股份有限公司 单位：人民币万元 法定代表人：李合军 主管会计工作的负责人：刘清科 会计机构负责人：董雪 第 3 页 共 3 页 非经营性资金占用 资金占用方名称 占用方与上市公 司的关联关系 上市公司核算的 会计科目 2023年期初 占用资金余额 2023年半年度 占用累计发生 金额（不含利 息） 2023年半年度 占用资金的利 息（如有） 2023年半年度 偿还累计发生 金额 2023年半年度期 末占用资金余额 占用形成原因 占用性质 控股股东、实际控制人及其附 属企业 非经营性占用 非经营性占用 小 计 - - - - 前控股股东、实际控制人及其 附属企业 非经营性占用 非经营性占用 小 计 - - - - 其他关联方及其附属企业 非经营性占用 非经营性占用 小 计 - - - - 总 计 - - - - 其它关联资金往来 资金往来方名称 往来方与上市公 司的关联关系 上市公司核算的 会计科目 2023年期初 往来资金余额 2023年半年度 往来累计发生 金额（不含利 息） 2023年半年度 往来资金的利 息（如有） 2 ...

安徽黄山胶囊股份有限公司 关于开展票据池业务的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 安徽黄山胶囊股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日召开 第五届董事会第三次会议和第五届监事会第三次会议，审议通过了《关于公司开 展票据池业务的议案》，为满足公司的发展需要、降低财务成本、提高资金使用 效率，同意公司在商业银行开展票据池业务，额度不超过 8000 万元，期限为自 董事会审议通过之日起 1 年，额度在上述业务期限内可滚动使用。本议案在公司 董事会审议权限范围内，无需提交股东大会审议。具体情况如下： 一、票据池业务情况 证券代码：002817 证券简称：黄山胶囊 公告编号：2023-024 1. 业务概述 票据池业务是指协议银行为满足企业客户对所持有的商业汇票进行统一管 理、统筹使用的需求，向企业提供的集票据托管和托收、票据质押池融资、票据 贴现、票据代理查询、业务统计等功能于一体的票据综合管理服务。 2. 合作银行 公司拟开展票据池业务的合作银行为国内资信较好的商业银行，具体合作银 行提请公司董事会授权公司管理层根据公司 ...

证券代码：002817 证券简称：黄山胶囊 公告编号：2023-022 安徽黄山胶囊股份有限公司 第五届董事会第三次会议决议公告 《2023 年半年度报告摘要》（公告编号：2023-021）和《2023 年半年度报告》 详见公司指定信息披露媒体《证券时报》、《上海证券报》、《中国证券报》和巨潮 资讯网（http://www.cninfo.com.cn）。 表决结果：同意票 7 票，反对票 0 票，弃权票 0 票。 2. 审议通过《关于公司开展票据池业务的议案》。 为满足公司的发展需要、降低财务成本、提高资金使用效率，公司拟在商业 银行开展票据池业务，额度不超过 8000 万元，独立董事对此事项已发表同意的 独立意见，详见公司于 2023 年 8 月 19 日在指定信息披露媒体《证券时报》、《上 海证券报》、《中国证券报》和巨潮资讯网（http://www.cninfo.com.cn）披露的 《关于开展票据池业务的公告》（公告编号：2023-024）、《独立董事关于第五届董 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 安徽黄山胶囊股 ...

（2）2023 年半年度，公司无任何形式的违规对外担保事项，也无以前期间 发生延续到报告期的违规对外担保事项。 二、关于公司开展票据池业务的独立意见 经核查，我们认为，公司目前经营情况良好，财务状况稳健。公司开展票据 池业务，可以将公司的应收票据和应付票据统筹管理，减少公司资金占用，优化 财务结构，提高资金利用率。因此，我们同意公司在商业银行开展票据池业务， 额度不超过 8000 万元，期限为自董事会审议通过之日起 1 年，额度在上述业务 期限内可滚动使用。 三、关于公司以专利权质押担保向银行申请贷款的独立意见 安徽黄山胶囊股份有限公司 独立董事关于第五届董事会第三次会议 相关事项的独立意见 我们作为安徽黄山胶囊股份有限公司（以下简称"公司"）的独立董事，根 据《公司法》、《中国证监会关于在上市公司建立独立董事制度的指导意见》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》、《公司章程》等有关规定，经过审慎、认真 的研究，现对公司第五届董事会第三次会议审议的相关事项发表如下独立意见： 一、关于公司 2023 年半年度控股股东及其他关联方资金占用、公司 ...

股票代码：002817 股票简称：黄山胶囊 编号：2023-001 投资者关系活动类 □特定对象调研 □分析师会议 别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 线上参与黄山胶囊 2022 年度网上业绩说明会的投资者 员姓名 时间 2023 年 05 月 10 日（星期三）下午 15:00-17:00 地点 "黄山胶囊投资者关系"微信小程序 董事、总经理：余超彪先生 上市公司接待人员 独立董事：沙风先生 姓名 副总经理：叶松林先生 副总经理：楚振华先生 财务总监：刘清科先生 副总经理、董事会秘书：张文政先生 1、问：现阶段来看，公司主要发展战略及重心是什么 答：尊敬的投资者您好！公司围绕"打造国内领先的医药 科技服务平台"这一长期目标。依托胶囊主营业务，深入 实施创新驱动发展战略，加大研发投入，加快设备更新和 投资者关系活动主 技术改造，持续提升生产车间智能化水平，进一步释放产 要内容介绍 能；加强技术合作与攻关，加大产品创新力度，着力提升 植物胶囊等新产品新工艺的研究，培育新的利润增长点。 继续深入推进产业结构布局优化，深化与战略客 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 143,226,804.73, representing a 41.37% increase compared to CNY 101,310,277.27 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 20,099,932.36, up 43.88% from CNY 13,969,880.23 year-on-year[5] - The net profit excluding non-recurring gains and losses was CNY 17,505,461.75, reflecting a significant increase of 78.84% compared to CNY 9,788,481.93 in the previous year[5] - The company's basic and diluted earnings per share both increased by 40.00%, reaching CNY 0.07 per share[5] - Total operating revenue for the current period reached ¥143,226,804.73, a significant increase of 41.4% compared to ¥101,310,277.27 in the previous period[32] - Net profit for the current period was ¥20,210,432.75, representing a 45.0% increase from ¥13,929,428.55 in the same period last year[33] - The company reported a total profit of ¥23,065,598.15, which is a 52.5% increase from ¥15,154,366.55 in the previous period[33] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to CNY 1,059,728,813.29, a 2.12% increase from CNY 1,037,692,058.04 at the end of the previous year[5] - The total equity attributable to the parent company reached ¥873,820,519.63, up from ¥853,758,112.73, indicating an increase of approximately 2.8%[30] - Total current assets amounted to ¥657,357,073.08, up from ¥618,271,712.89, reflecting a growth of approximately 6.3%[29] - Total liabilities increased slightly to ¥185,355,051.05 from ¥183,481,821.74, showing a growth of about 1%[30] Cash Flow - The net cash flow from operating activities decreased by 168.43%, amounting to -CNY 16,148,615.37, compared to CNY 23,600,068.31 in the same period last year[5] - Cash flow from operating activities showed a net outflow of ¥16,148,615.37, contrasting with a net inflow of ¥23,600,068.31 in the prior period[35] - The company reported a 135.32% increase in net cash flow from investing activities, amounting to CNY 17,693,720, mainly due to the redemption of financial products[22] - The company experienced a significant increase in cash inflow from investment activities, totaling ¥46,183,201.83, compared to a net outflow of -¥130,754,044.31 in the previous period[36] - The net increase in cash and cash equivalents was CNY 13,900,880, reflecting a growth of 127.47% compared to the previous year[25] - Cash and cash equivalents at the end of the period totaled ¥348,562,527.05, an increase from ¥234,839,284.78 at the end of the previous period[37] Shareholder Information - The total number of common shareholders at the end of the reporting period is 28,152[27] - The largest shareholder, Shandong Lutai Holdings, holds 29.99% of shares, totaling 89,699,541 shares[27] - The number of shares held by the top ten shareholders includes significant stakes from both state-owned and individual investors, with the top two shareholders holding a combined 38.05%[27] Accounts Receivable - Accounts receivable increased by 58.63%, totaling CNY 51,775,800, primarily due to increased sales and delayed collection[9] - Accounts receivable rose to ¥140,080,825.88 from ¥88,304,996.07, indicating an increase of about 58.6%[29] Research and Development - Research and development expenses increased to ¥4,868,433.54, up from ¥3,869,928.41 in the previous period, indicating a focus on innovation[32] Other Information - The company received government subsidies amounting to CNY 2,810,849.06 during the quarter, contributing to its financial performance[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[28] - Other comprehensive income after tax was reported at -¥46,906.81, compared to -¥11,474.97 in the previous period[33]

Financial Performance - The company's operating revenue for 2022 was ¥428,318,791.71, representing a 12.75% increase compared to ¥379,891,008.70 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥60,850,372.05, a 6.97% increase from ¥56,887,811.36 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥51,050,352.05, up 5.69% from ¥48,301,265.66 in the previous year[23] - The total assets at the end of 2022 were ¥1,037,692,058.04, down 1.53% from ¥1,053,820,293.60 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥853,758,112.73, an increase of 5.44% from ¥809,694,572.19 at the end of 2021[23] - The basic earnings per share for 2022 were ¥0.20, a 5.26% increase from ¥0.19 in 2021[23] - The diluted earnings per share for 2022 were also ¥0.20, reflecting the same increase of 5.26% from the previous year[23] - The weighted average return on equity for 2022 was 7.34%, slightly up from 7.25% in 2021[23] Cash Flow - The net cash flow from operating activities was ¥83,016,820.72, a decrease of 3.57% from ¥86,089,406.99 in 2021[23] - Operating cash inflow increased by 10.09% to ¥391,715,445.37, while operating cash outflow rose by 14.45% to ¥308,698,624.65[61] - Net cash flow from operating activities decreased by 3.57% to ¥83,016,820.72[61] - Investment cash inflow surged by 258.65% to ¥545,466,959.68, while investment cash outflow increased by 204.74% to ¥559,132,194.23[61] - Net cash flow from investment activities improved by 56.47% to -¥13,665,234.55[62] - Cash and cash equivalents decreased by 124.69% to -¥25,285,572.34, primarily due to reduced financing cash flow[62] Revenue Breakdown - The company's total revenue for Q1 2022 was approximately CNY 101.31 million, with a peak in Q4 2022 at CNY 127.14 million, indicating a quarterly fluctuation of 25.3%[27] - Net profit attributable to shareholders for Q2 2022 was CNY 17.55 million, while Q4 2022 saw a decline to CNY 12.75 million, reflecting a decrease of 27.5%[27] - The sales of gel capsules accounted for 79.17% of total revenue, with a revenue of ¥339,080,226.02, up 10.88% from ¥305,805,926.12 in 2021[50] - Domestic sales reached ¥397,971,632.29, making up 92.91% of total revenue, while international sales surged by 157.43% to ¥30,347,159.42, representing 7.09% of total revenue[50] Research and Development - Research and development investment amounted to 14.98 million yuan, with 8 patent applications filed, including 3 invention patents[47] - R&D investment rose by 11.47% to ¥14,980,970.94, accounting for 3.50% of operating revenue[59] - The company has initiated several new product development projects, including hydroxypropyl methylcellulose hollow capsules, aiming for annual sales of 4 billion pieces[58] - Research and development expenses rose by 11.47% to ¥14,980,970.94 in 2022, compared to ¥13,439,131.79 in 2021[58] Market Strategy - The pharmaceutical industry is transitioning towards high-quality development, with a focus on product innovation and international expansion as outlined in the "14th Five-Year Plan" for the pharmaceutical industry[33] - The company is enhancing brand promotion in the traditional Chinese medicine sector to adapt to market changes and maintain healthy growth[34] - The company aims to enhance its competitive advantage through continuous investment in technology research and development, aiming to become a leading pharmaceutical technology service platform in China[45] - The company plans to optimize its industrial structure and expand international market presence to overcome development bottlenecks[74] - The company is expanding its human resources management to address the potential mismatch between talent supply and business growth needs[77] Governance and Compliance - The company held three shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[81] - The company maintains independent operations from its controlling shareholder, ensuring no interference in decision-making[85] - The company has established a complete and independent financial accounting system, allowing for autonomous financial decision-making[87] - The company has established rules for related party transactions to ensure they follow market principles[89] - The company conducted a self-assessment of its governance structure, finding it compliant with relevant laws and regulations, with no major defects affecting operations[135] Shareholder Information - The company plans to distribute a cash dividend of ¥0.6 per 10 shares, totaling approximately ¥17,945,908.20 based on 299,098,170 shares[4] - The company reported a cash dividend of RMB 17,945,890.20 for the fiscal year, which represents 29.49% of the distributable profit of RMB 411,140,417.21[124] - The total number of shares increased from 213,641,550 to 299,098,170 after a capital reserve conversion, resulting in a 40.00% increase in total shares[180] - The largest shareholder, Shandong Lutai Holding Group, holds 29.99% of the shares, totaling 89,699,541 shares[187] Employee Management - The total number of employees at the end of the reporting period was 681, with 493 in production, 30 in sales, 81 in technical roles, 7 in finance, and 70 in administration[118] - The company implemented a performance-oriented salary system, enhancing employee motivation and retention through various incentive mechanisms[119] - The training completion rate for the year was 100%, with 429 frontline employees trained in SOP and professional knowledge, and 59 new employees receiving pre-job skills training[121] - The company has established a comprehensive training management system, combining internal and external training to enhance employee skills[121] Environmental and Social Responsibility - The company invested in supercritical CO2 heating and cooling systems and catalytic combustion systems, effectively reducing energy consumption and emissions[136] - The company donated 154,500 yuan to social welfare activities, including blood donation and support for disadvantaged employees[137] - The company emphasizes the importance of timely and accurate information disclosure to protect the rights of shareholders and creditors[134] Future Outlook - The company’s future outlook remains positive, with expectations of continued growth in revenue and market share[98] - The company has set a revenue target of 1 billion RMB for the next fiscal year, indicating a growth expectation of 25%[105] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[105] - The company aims to strengthen its competitive position in the industry through potential mergers and acquisitions, although no specific targets were mentioned[98]